Chemistry:Esprolol
From HandWiki
Esprolol, also known as (S)-ACC-9369, is a beta blocker which was under development for the treatment of angina pectoris, anxiety disorders, and migraine.[1][2][3] It is taken sublingually and has a rapid onset of action, short time to peak, and short duration.[1][3] The drug is a prodrug of amoxolol, which is formed from esprolol via esterase enzymes.[3] It is a selective β1-adrenergic receptor antagonist.[3][4] Esprolol was under development by Selectus Pharmaceuticals.[1][2] It reached phase 2 clinical trials for all indications prior to the discontinuation of its development in 2001.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "Esprolol". 25 June 2001. https://adisinsight.springer.com/drugs/800011278.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Esprolol Hydrochloride with Synapse". 30 May 2026. https://synapse.patsnap.com/drug/0327330e46ab4d27b44e099cbf18a5c5.
- ↑ 3.0 3.1 3.2 3.3 "Esprolol hydrochloride: a new beta adrenergic antagonist with a rapid onset of effect". Heart Dis 2 (2): 146–150. 2000. PMID 11728252.
- ↑ "Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines". Clin Pharmacokinet 41 (7): 505–516. 2002. doi:10.2165/00003088-200241070-00004. PMID 12083978. "A sublingual β1-selective blocker, esprolol, is now being evaluated in clinical trials.[30]".
 |  |
